[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"meibomian-gland-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:meibomian-gland-dysfunction":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,51,76,99,123],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100638090","phase-4-ocular-surface-health-and-tear-film-stability-with-a-nasal-spray-dry-eye-treatment-100638090",false,"NCT07606625","Ocular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment","The Impact of Varenicline Nasal Spray 0.03mg Dry Eye Treatment on Ocular Surface Health, Tear Film Stability, and Ocular Discomfort","Inclusion Criteria:\n\n* Is 18 years of age and has full legal capacity to volunteer (no max age requirement)\n* Baseline Ocular Surface Disease Index (OSDI) \\>13\n* Has mild to moderate MGD\n* Has best corrected visual acuity of 20\u002F40 or better\n* Has had an oculo-visual examination in the last two years\n* Is willing to continue other daily dry eye management regimen (e.g., warm compresses, and\u002For eyelid margin cleaning)\n* Is willing to discontinue other prescription medications for dry eye disease (DED) management\n* Is willing to stop any topical eye drops before all planned visits\n* Has read, understood, and completed the informed consent letter\n\nExclusion Criteria:\n\n* Is participating in any other type of clinical or research study\n* Is currently pregnant, nursing, lactating, or planning a pregnancy\n* Is currently having \\>50% blockage of Meibomian glands in more than two eyelids or significant atrophy (i.e., severe MGD)\n* Is currently using any topical ocular medications\n* Has chronic or currently active sinus related problems\n* Has blepharitis \\> grade 1\n* Has active ocular infections\n* Has a condition or in a situation which, in the examiner's opinion, may put the subject at significant risk, may confound the study results, or may significantly interfere with their participation in the study\n* Has received Rx DED treatment within one week of enrollment\n* Has received any thermal or light-based DED treatment within 30 days of enrollment\n* Has significant corneal epithelial defects\n* Has abnormal eyelid anatomy\n* Has corneal neuropathic pain\n* Has chronic or recurrent epistaxis (nosebleeds), coagulation disorders, or other conditions that may have led to a clinically significant increased risk of bleeding\n* Has any intraocular surgery including trabeculectomy (MIGS, laser, or small incision glaucoma surgery allowed), extraocular surgery in either eye within 3 months, or refractive surgery within 12 months of enrollment\n* Has a known allergy to a product used in this study","ALL","18 Years",{"count":19,"type":20},65,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The purpose of this study is to examine the impact of nasal spray treatment on Meibomian gland function and ocular surface health in symptomatic dry eye patients with mild to moderate Meibomian gland dysfunction (MGD).",[26,27],"Dry Eye","Meibomian Gland Dysfunction",[29,30,31,32,33,34,35,36,37],"Dry eye disease","Meibomian gland dysfunction","Varenicline","Nasal spray dry eye treatment","Tear lipid layer","Tear thinning","Tear production","Tear film stability","Ocular discomfort","RECRUITING","2026-05-22",{"date":41,"type":42},"2026-05-27","ACTUAL",{"date":44,"type":42},"2026-03-06",{"date":46,"type":20},"2026-12-31",{"name":48,"class":49},"University of California, Berkeley","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":50},"100344658","efficacy-and-safety-of-thermic-devices-in-the-treatment-of-meibomian-gland-dysfunction-100344658","NCT03767530","Efficacy and Safety of Thermic Devices in the Treatment of Meibomian Gland Dysfunction","Inclusion Criteria:\n\n* Patients diagnosed with:\n\n  * Dry eye syndrome with meibomian gland dysfunction alone or in combination of other type of dry eye.\n  * Patients who were previously treated with eyelid massages and warm compresses without any improvement.\n\nExclusion Criteria:\n\n* Pregnant women.\n* History of ocular surgery within three months prior to inclusion.\n* History of trauma, infection or inflammation within three months prior to inclusion.\n* Contact lens use in the last week before inclusion.\n* Patients with active ocular allergic disease.\n* Patient with microbial keratitis.",{"count":58,"type":20},42,[60],"NA","Dry eye syndrome is a common eye disease that affects 1 to 2 out of 10 persons around the planet. One common cause of this disease is the meibomian gland dysfunction. Meibomian glands are very small glands located at the rim of the eyelids that produce an oily substance that prevents the evaporation of tears. When these glands are compromised, the tear film evaporates quickly and the eyes dry up. This disease presents as eye irritation, foreign body sensation, inflammation, etc. The treatment of choice for MGD is eyelid massage and warm compresses 2 times a day. However, these treatments not always work perfectly, and as a result, patients find it hard to follow doctor's orders. Another kind of treatment is thermal therapy. There are several devices that are designed to apply heat on the eyelids, such as Lipiflow, MiBo Thermoflo, and Blephasteam. In this study, we want to find out whether thermal therapy with MiBo Thermoflo works better than warm compresses and eyelid massage use in the treatment of dry eye caused by MGD. To do this, we will select several patients and will assign them randomly to either the group with thermal therapy with MiBo Thermoflo or to the group with warm compresses and eyelid massage. The Mibo group will receive 3 sessions of thermal therapy at 2 weeks interval and the control group warm compresses and eyelid massage 2 times per day. All subjects will have a follow up of 24 weeks and we will compare results for both groups at the end of the study.",[27],[30,64,65,29,66],"Mibo","MGD","Thermic devices","2026-05-04",{"date":69,"type":42},"2026-05-08",{"date":71,"type":42},"2019-09-01",{"date":73,"type":20},"2027-12-20",{"name":75,"class":49},"Universidad Autonoma de Nuevo Leon",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100533027","therapeutic-efficacy-and-safety-of-non-invasive-rf-treatment-in-refractory-mgd-100533027","NCT06220474","Therapeutic Efficacy and Safety of Non-Invasive RF Treatment in Refractory MGD","Therapeutic Efficacy and Safety of Non-Invasive Radiofrequency Treatment in Patients With Refractory Meibomian Gland Dysfunction: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age 18 or more\n2. Bilateral dry eye disease as confirmed by presence of both symptoms and signs 2.1 Symptoms: Abnormal result on the Standard Patient Evaluation of Eye Dryness Questionnaire (SPEED) dry eye symptom questionnaire (≥5) 2.2 Signs: Abnormal result in at least one of the following three clinical tests - tear osmolarity, NIKBUT and corneal staining for punctate epithelial erosions and,\n3. Bilateral moderate to severe meibomian gland dysfunction - at least Grade 1 meibum quality (cloudy appearance) and Grade 2 meibum expressibility (moderate pressure required). And,\n4. Refractory MGD - The failure to respond to at least three types of conventional therapy, including artificial tears, topical or systemic antibiotics and anti-inflammatory treatments and the aforementioned heat-based therapies, over a period of at least 2 years\n5. Fitzpatrick skin type I-IV - Type V and VI skinned subjects are excluded from the study due to the high risk of pain and focal hypopigmentation\n6. Mentally fit to give informed consent\n\nExclusion Criteria:\n\n1. Fitzpatrick skin type V-VI\n2. History of eyelid scarring\n3. Infrared meibography evidence of significant acinar gland atrophy (dropout of \\>30%) - these patients have been shown not to benefit from heat-based therapies due to end-stage disease\n4. Pregnancy or lactation\n5. Active corneal disease such as infectious keratitis, allergic keratoconjunctivitis, pterygium, exposure keratopathy, lagophthalmos, trichiasis or dellen\n6. Current systemic intake of photosensitive medications, including tetracycline group of drugs.\n7. History of corneal abnormality or surgery within 3 months",{"count":84,"type":20},112,[60],"The goal of this prospective, 24-week, double-masked, randomized, sham-controlled clinical trials to compare clinical efficacy and safety of RF and MGX with MGX alone in patients with meibomian gland dysfunction-related dry eye disease. The main question it aims to answer is whether radiofrequency treatment and meibomian gland expression is more effective in improving tear breakup time, as measured using non-invasive video keratography, compared with meibomian gland expression alone, in patients with refractory meibomian gland dysfunction-related dry eye disease.\n\nParticipants will be divided into two groups, one group will receive RF treatment followed with MGX and another will receive sham treatment with MGX.",[88,27],"Dry Eye Syndromes","2026-04-24",{"date":91,"type":42},"2026-04-27",{"date":93,"type":42},"2024-10-22",{"date":95,"type":20},"2027-12-31",{"name":97,"class":49},"The University of Hong Kong",2,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":21,"phases":108,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":98},"100544623","photobiomodulation-with-red-vs-blue-light-rebel-100544623","NCT06371300","Photobiomodulation With REd vs BluE Light (REBEL)","Photobiomodulation of the Ocular Surface and Eyelids With Different Wavelengths: REd vs BluE Light (REBEL)","Inclusion Criteria:\n\n* Individuals with dry eye disease symptoms (Ocular Surface Disease Index questionnaire (OSDI) score ≥ 13 or Dry Eye Questionnaire (DEQ5) score \\> 6) and signs (tear film instability measured with non-invasive tear break-up time \\\u003C 10 s or ocular surface damage measured using special dyes placed on the front surface of the eyes that temporarily stains any aggravated or damaged cells: \\> 5 corneal spots, \\> 9 conjunctival spots or lid margin staining ≥ 2mm in length and ≥ 25% in width)\n* Individuals need to also have Meibomian gland dysfunction. The diagnosis of Meibomian gland dysfunction depends on how many of 5 glands in the central lower eyelid can express oil, and the quality of the oil. A diagnosis is made if there is decreased expressibility (grade 1-3 on the Pflugfelder scale) and reduced quality of oil (grade 1-3 on Bron scale). Any presence of gland blockage and\u002For loss of oil glands grade 1 to grade 4 of either eyelid \\[Pult and Reide-Pult, 2013\\]) will also justify a diagnosis of Meibomian gland dysfunction.\n* Individuals will also need to have ocular demodicosis, diagnosed by clinical observation on slit lamp biomicroscope based on signs including collarettes around the base of lashes, visible Demodex tails, or excessive pouting of lash follicles in those with good lid hygiene where Demodex was confirmed by secondary means such as visible Demodex tails.\n* Age ≥ 18 years, male or female\n* Able to provide written consent in English\n* Able to attend a total of 4 visits: 3 treatment visits and followed up for 1 month after final treatment\n\nExclusion Criteria:\n\n* Pregnancy\n* Ocular light-based therapies including intense pulsed light (IPL) or LLLT treatment within the past 1 month or during study period in addition to those provided in the study\n* Contact lens wear in the past 2 weeks or during study period\n* Other active ocular surface diseases or history of ocular surgery or corneal infections the past 6 months",{"count":107,"type":20},36,[60],"The use of photobiomodulation or low-level light therapy (LLLT) in the ophthalmic field stemmed from dermatology which has shown impact on skin blood flow and regeneration. There has been a rise in clinical interest with emerging evidence in the benefits of photobiomodulation in managing chronic inflammatory conditions such as dry eye disease including improvements in ocular discomfort symptoms, tear film stability and tear volume. Despite the observed clinical benefits, limited research has been done to compare photobiomodulation utilising different wavelengths, as most research on dry eye disease has focused on red wavelengths. It has been purported that blue wavelengths may disrupt microbial growth while red wavelengths stimulate energy production and hence increase heat in the affected tissues, although research into these differential impacts at the ocular surface and external eye has been limited. Hence, the aim of this exploratory clinical trial is to compare the impact of using LLLT incorporating red versus blue wavelengths on eyelid haemodynamics and microbiome, as well as conventional ocular surface measures of patients with dry eye disease and blepharitis (inflammation of the eyelids).\n\nParticipants with dry eye disease, oil gland disruption and blepharitis will receive 3 treatments with these LLLT, each separted by 1 week apart, and followed up to 1 month after the final treatment session. Participants will be randomised to either of 3 groups: Red light only group, Red + Blue light group, or a sham treatment group.",[88,27,111],"Blepharitis",[113],"Low-level light therapy","2026-01-19",{"date":116,"type":42},"2026-01-21",{"date":118,"type":42},"2024-05-01",{"date":120,"type":20},"2026-12-30",{"name":122,"class":49},"Aston University",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":130,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":21,"phases":133,"briefSummary":134,"conditions":135,"keywords":137,"overallStatus":140,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":50},"100556504","phase-4-itear-single-center-open-label-single-arm-study-100556504","NCT06525961","iTear Single-center, Open-label, Single-arm Study","A Single-center, Open-label, Single-arm Study to Evaluate the Effectiveness and Safety of Extra Nasal Neurostimulator in Patients With Dry Eye Disease Dissatisfied With Artificial Tears","Inclusion Criteria:\n\nEach patient must meet all the following criteria to be enrolled in this study:\n\n1. Provided informed consent, approved by the Institutional Review Board (IRB), to participate in the study.\n2. Reported use of artificial tears for DED within 30 days of Visit 1.\n3. Ocular Surface Disease Index (OSDI) ≥ 23 (with no more than 3 N\u002FA in the answers).\n4. Anesthetized Schirmer Test Score ≤ 10 mm\u002F5 min in at least one eye.\n\nExclusion Criteria:\n\nPatients who meet any of the following criteria will be excluded from the study:\n\n1. Used extranasal or intranasal neurostimulator within 30 days of Visit 1.\n2. Participation in any clinical trial with an investigational drug or device within 30 days of Visit 1.\n3. In the opinion of the investigator, any condition that could impair study participation\u002Focular evaluation or the potential risks of participation outweigh the potential benefits.",true,{"count":132,"type":20},30,[23],"This study aims to evaluate the effectiveness and safety of a device, iTEAR100 Neurostimulator (the device), which is designed to help people with Dry Eye Disease (DED) who are not satisfied with using artificial tears. The study will last three months and take place at one location. Thirty participants will use the iTEAR100 Neurostimulator, which stimulates the outside of the nose to help with dry eye symptoms.\n\nParticipants will have three main visits: one at the start (Day 0), one after 30 days (Day 30), and one at the end of the study (Day 90). For the first 30 days, they will use the device twice a day for 30 seconds on each side of the nose. After that, they will use it as needed for the next 60 days.\n\nBefore starting the treatment, participants will undergo tests to measure their initial eye condition. The effectiveness of the device will be checked by comparing these baseline measurements to those taken on Day 30 and Day 90. Participants will also fill out a questionnaire about their eye symptoms on Day 14.\n\nThe main measure of success is how much the participants' symptoms improve on the Ocular Surface Disease Index (OSDI) from Day 0 to Day 30. Other measures include changes in tear production, tear quality, and eye health from Day 0 to Days 30 and 90. Participants' safety will be monitored by tracking any adverse events (side effects) throughout the study.",[136,88,26,27],"Dry Eye Disease",[26,138,88,139],"DED","Meibomian Gland Dysfunction (MGD)","NOT_YET_RECRUITING","2024-07-23",{"date":143,"type":42},"2024-07-29",{"date":145,"type":20},"2024-08",{"date":147,"type":20},"2026-01",{"name":97,"class":49}]